Three opioid manufacturers have made an $18 billion offer to settle lawsuits over their roles in the opioid epidemic. A group of 21 US states has rejected the offer.
Category: US Pharmaceuticals
The FDA has granted Ofev (nintedanib) a breakthrough therapy designation for chronic fibrosing interstitial lung disease, according to Boehringer Ingelheim.Read More
A panel of experts earlier this month recommended that the US Food and Drug...Read More
The US FDA has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma.Read More
The US Food and Drug Administration approved Xenleta (lefamulin) to treat adults with...Read More
A new drug application for a triple combination regimen of elexacaftor plus tezacaftor/ivacaftor to treat cystic fibrosis has been submitted to the FDA, with a request for priority review.Read More
Pulmonary fibrosis drugs pirfenidone and nintedanib appear to increase longevity and decrease hospitalizations in IPF patients.Read More